Small molecule antagonists for chemokine CCR3 receptors

The chemokine receptor CCR3 is believed to play a role in the development of allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis. Despite the conflicting results that have been reported regarding the importance of eosinophils and CCR3 in allergic inflammation, inhibition of this receptor with small molecule antagonists is thought to provide a valuable approach for the treatment of these diseases. This review describes the structure–activity relationships (SAR) of small molecule CCR3 antagonists as reported in the scientific and patent literature. Various chemical classes of small molecule CCR3 antagonists have been described so far, including (bi)piperidine and piperazine derivatives, N‐arylalkylpiperidine urea derivatives and (N‐ureidoalkyl)benzylpiperidines, phenylalanine derivatives, morpholinyl derivatives, pyrrolidinohydroquinazolines, arylsulfonamides, amino‐alkyl amides, imidazole‐ and pyrimidine‐based antagonists, and bicyclic diamines. The (N‐ureidoalkyl)benzylpiperidines are the best studied class in view of their generally high affinity and antagonizing potential. For many of these antagonists subnanomolar IC50 values were reported for binding to CCR3 along with the ability to effectively inhibit intracellular calcium mobilization and eosinophil chemotaxis induced by CCR3 agonist ligands in vitro. © 2009 Wiley Periodicals, Inc. Med Res Rev, 30, No. 5, 778–817, 2010

[1]  Erik De Clercq,et al.  The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). , 2009, Biochemical pharmacology.

[2]  R. Horuk,et al.  Chemokine receptor antagonists: part 2 , 2009, Expert opinion on therapeutic patents.

[3]  R. Horuk,et al.  Chemokine receptor antagonists: Part 1 , 2009, Expert opinion on therapeutic patents.

[4]  J. Barrish,et al.  Urea based CCR3 antagonists employing a tetrahydro-1,3-oxazin-2-one spacer. , 2009, Bioorganic & medicinal chemistry letters.

[5]  R. Horuk,et al.  Chemokine receptor antagonists: overcoming developmental hurdles , 2009, Nature Reviews Drug Discovery.

[6]  M. Takeuchi,et al.  Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition. , 2008, Bioorganic & medicinal chemistry.

[7]  C. Mackay,et al.  Moving targets: cell migration inhibitors as new anti-inflammatory therapies , 2008, Nature Immunology.

[8]  A. Tebben,et al.  From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[9]  I. Kariv,et al.  From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis. , 2008, Bioorganic & medicinal chemistry letters.

[10]  A. Viola,et al.  Chemokines and their receptors: drug targets in immunity and inflammation. , 2008, Annual review of pharmacology and toxicology.

[11]  M. Takeuchi,et al.  Synthesis and structure-activity relationships of N-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists. , 2008, Bioorganic & medicinal chemistry.

[12]  T. Williams,et al.  Small Molecule Receptor Agonists and Antagonists of CCR3 Provide Insight into Mechanisms of Chemokine Receptor Activation* , 2007, Journal of Biological Chemistry.

[13]  M. Gillard,et al.  Pyrazolone methylamino piperidine derivatives as novel CCR3 antagonists. , 2007, Bioorganic & medicinal chemistry letters.

[14]  M. Kaneko,et al.  A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor. , 2007, European journal of pharmacology.

[15]  I. Kariv,et al.  CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.

[16]  F. Kalkbrenner,et al.  Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. , 2007, American journal of respiratory cell and molecular biology.

[17]  G. Trainor,et al.  2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity. , 2006, Bioorganic & medicinal chemistry letters.

[18]  L. Hassman,et al.  A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation , 2006, Proceedings of the National Academy of Sciences.

[19]  Kevin Wei,et al.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development , 2006, The Journal of experimental medicine.

[20]  T. Williams,et al.  Chemokines and their receptors in allergic disease. , 2006, The Journal of allergy and clinical immunology.

[21]  M. Kaneko,et al.  A Novel, Selective, and Orally Available Antagonist for CC Chemokine Receptor 3 , 2006, Journal of Pharmacology and Experimental Therapeutics.

[22]  M. Kaneko,et al.  In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031. , 2006, Biochemical and biophysical research communications.

[23]  J. Shaw,et al.  Chemokine blockers--therapeutics in the making? , 2006, Trends in pharmacological sciences.

[24]  M. Thelen,et al.  The Chemokine SDF-1/CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes* , 2005, Journal of Biological Chemistry.

[25]  Y. Wan,et al.  The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: antagonists versus agonists. , 2005, Bioorganic & medicinal chemistry letters.

[26]  Y. Wan,et al.  The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[27]  J. Trzăskos,et al.  N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[28]  F. Birke,et al.  Pyrrolidinohydroquinazolines--a novel class of CCR3 modulators. , 2005, Bioorganic & medicinal chemistry letters.

[29]  G. Trainor,et al.  Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. , 2005, Journal of medicinal chemistry.

[30]  P. Schmid‐Grendelmeier,et al.  Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective , 2005, Current opinion in pulmonary medicine.

[31]  S. Escher,et al.  Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases , 2004, Allergy.

[32]  S. Orkin,et al.  A Critical Role for Eosinophils in Allergic Airways Remodeling , 2004, Science.

[33]  E. Lenkiewicz,et al.  Defining a Link with Asthma in Mice Congenitally Deficient in Eosinophils , 2004, Science.

[34]  G. Trainor,et al.  Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists. , 2004, Bioorganic & medicinal chemistry letters.

[35]  Lauren Cohn,et al.  Asthma: mechanisms of disease persistence and progression. , 2004, Annual review of immunology.

[36]  R. Wilhelm,et al.  Design and synthesis of novel CCR3 antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[37]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[38]  T. Williams,et al.  Variations in Eosinophil Chemokine Responses: An Investigation of CCR1 and CCR3 Function, Expression in Atopy, and Identification of a Functional CCR1 Promoter1 , 2003, The Journal of Immunology.

[39]  M. Ishikawa,et al.  Structure-activity relationships of 2-(benzothiazolylthio)acetamide class of CCR3 selective antagonist. , 2003, Chemical & pharmaceutical bulletin.

[40]  L. Traphagen,et al.  Identification and Characterization of Novel Antagonists of the CCR3 Receptor , 2003, Journal of biomolecular screening.

[41]  G. Trainor,et al.  Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. , 2002, Journal of medicinal chemistry.

[42]  G. Trainor,et al.  CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships. , 2002, Bioorganic & medicinal chemistry letters.

[43]  P. Barnes,et al.  Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. , 2002, American journal of respiratory and critical care medicine.

[44]  P. Murphy.  International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature , 2002, Pharmacological Reviews.

[45]  R. Geha,et al.  CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. , 2002, The Journal of clinical investigation.

[46]  D. Friend,et al.  The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[48]  H. Sarau,et al.  Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1. , 2001, Bioorganic & medicinal chemistry letters.

[49]  H. Sarau,et al.  Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2. , 2001, Bioorganic & medicinal chemistry letters.

[50]  C. Owen.  Chemokine receptors in airway disease: which receptors to target? , 2001, Pulmonary pharmacology & therapeutics.

[51]  M. Ishikawa,et al.  Discovery of a novel CCR3 selective antagonist. , 2001, Bioorganic & medicinal chemistry letters.

[52]  M. Ishikawa,et al.  Identification of a potent and nonpeptidyl ccr3 antagonist. , 2001, Biochemical and biophysical research communications.

[53]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[54]  H. Sarau,et al.  Identification of Potent, Selective Non-peptide CC Chemokine Receptor-3 Antagonist That Inhibits Eotaxin-, Eotaxin-2-, and Monocyte Chemotactic Protein-4-induced Eosinophil Migration* , 2000, The Journal of Biological Chemistry.

[55]  F. Finkelman,et al.  Murine Eotaxin-2: A Constitutive Eosinophil Chemokine Induced by Allergen Challenge and IL-4 Overexpression1 , 2000, The Journal of Immunology.

[56]  M. Peck,et al.  A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3 , 2000, The Journal of Biological Chemistry.

[57]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[58]  S. Bel,et al.  Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. , 1999, Journal of immunology.

[59]  J. Bernstein,et al.  Polymorphisms in the human CC chemokine receptor-3 gene. , 1998, Biochimica et biophysica acta.

[60]  S. Rankin,et al.  Kinetics of Eotaxin Generation and Its Relationship to Eosinophil Accumulation in Allergic Airways Disease: Analysis in a Guinea Pig Model In Vivo , 1997, The Journal of experimental medicine.

[61]  C. Mackay,et al.  Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils , 1996, The Journal of experimental medicine.

[62]  P. Foster,et al.  Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model , 1996, The Journal of experimental medicine.